High-throughput screening remains one of the most powerful, unbiased approaches for small molecule drug discovery.
In this white paper, SAMDI Tech CSO, Zack Gurard-Levin, discusses the important aspects to consider when choosing the right methodology for drug discovery.
- Traditional label-dependent approaches vs. novel label-free technologies
- How researchers determine which methodology offers the most promising path forward for their target
- How to take into account assay sensitivity, data quality, costs, and speed
- When to outsource to contract research organizations with an established discovery infrastructure to lead hit identification and hit-to-lead programs